Dendreon Corp. (Nasdaq: DNDN) swung to a profit for the fourth quarter of 26 cents per share compared with a loss of 64 cents per share in the year ago period but warned of significant charges in the first quarter and forecast lower than expected sales of Provenge in the first quarter. Shares of the biotechnology company planed $2.91 to $11.95.
Dendreon Expects More Modest Provenge Sales
February 27, 2012 at 14:14 PM EST
